BBA
KRYS icon

Baker Bros. Advisors’s Krystal Biotech KRYS Stock Holding History

Baker Bros. Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-169,934
Closed -$26.6M – 93
2024
Q4 		$26.6M Hold
169,934
– – 0.28% 38
2024
Q3 		$30.9M Hold
169,934
– – 0.32% 35
2024
Q2 		$31.2M Hold
169,934
– – 0.4% 32
2024
Q1 		$30.2M Hold
169,934
– – 0.38% 36
2023
Q4 		$21.1M Hold
169,934
– – 0.24% 37
2023
Q3 		$19.7M Hold
169,934
– – 0.11% 37
2023
Q2 		$20M Sell
169,934
-132,782
-44% -$13.6M 0.12% 44
2023
Q1 		$24.2M Hold
302,716
– – 0.13% 36
2022
Q4 		$24M Sell
302,716
-119,469
-28% -$8.87M 0.14% 37
2022
Q3 		$29.4M Sell
422,185
-385,550
-48% -$27.9M 0.19% 36
2022
Q2 		$53M Hold
807,735
– – 0.3% 22
2022
Q1 		$53.7M Hold
807,735
– – 0.31% 26
2021
Q4 		$56.5M Buy
807,735
+200,000
+33% +$11.6M 0.27% 34
2021
Q3 		$31.7M Hold
607,735
– – 0.14% 51
2021
Q2 		$41.3M Sell
607,735
-152,677
-20% -$10.7M 0.18% 43
2021
Q1 		$58.6M Buy
760,412
+61,538
+9% +$4.47M 0.25% 33
2020
Q4 		$41.9M Sell
698,874
-76,318
-10% -$3.81M 0.16% 39
2020
Q3 		$33.4M Sell
775,192
-42,439
-5% -$1.84M 0.13% 39
2020
Q2 		$33.9M Sell
817,631
-128,840
-14% -$6.2M 0.15% 38
2020
Q1 		$40.9M Sell
946,471
-88,203
-9% -$4.61M 0.25% 30
2019
Q4 		$57.3M Hold
1,034,674
– – 0.3% 27
2019
Q3 		$35.9M Hold
1,034,674
– – 0.24% 34
2019
Q2 		$41.7M Buy
1,034,674
+250,000
+32% +$8.17M 0.28% 32
2019
Q1 		$25.8M Hold
784,674
– – 0.17% 36
2018
Q4 		$16.3M Buy
784,674
+670,000
+584% +$14M 0.13% 35
2018
Q3 		$2.02M Sell
114,674
-85,326
-43% -$1.43M 0.01% 85
2018
Q2 		$2.97M Hold
200,000
– – 0.02% 92
2018
Q1 		$2.02M Hold
200,000
– – 0.02% 92
2017
Q4 		$2.1M Hold
200,000
– – 0.02% 97
2017
Q3 		$1.99M Buy
+200,000
New +$2.02M 0.02% 98

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Baker Bros. Advisors's KRYS Position: Q1 2025 in Review

Baker Bros. Advisors sold out of Krystal Biotech (KRYS) in Q1 2025, closing a stake of 169,934 shares — an estimated $26.6M sold.

Baker Bros. Advisors first reported a position in KRYS in Q3 2017 and held it in 30 quarters. The position peaked at $58.6M in Q1 2021. 299 funds tracked by Wall St. Rank hold KRYS as of Q1 2025.

  • Baker Bros. Advisors reported no remaining Krystal Biotech position as of Q1 2025 after selling out during the quarter.
  • Baker Bros. Advisors sold 169,934 Krystal Biotech shares in Q1 2025, an estimated $26.6M.
  • Baker Bros. Advisors first reported a position in Krystal Biotech in Q3 2017 and held it in 30 quarters.
  • Baker Bros. Advisors's Krystal Biotech position peaked at $58.6M in Q1 2021.
  • 299 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2025.

Based on Baker Bros. Advisors's 13F filing for Q1 2025, filed 15 May 2025.